BOSTON--(BUSINESS WIRE)--Care Access—a global research site enabling clinical research participation for more people—is actively enrolling participants at its Pottsville, Pa., location to study the effect of an investigational treatment for a common form of liver disease that is not related to alcohol consumption.
Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD) where fat buildup in the liver can lead to inflammation and scarring, known as cirrhosis. The disease can cause severe liver damage with few or no symptoms. If symptoms do occur, they can include fatigue and abdominal pain.
While a family history of NASH may increase one’s risk of getting the disease, certain health conditions may also increase one’s risk, including obesity, high cholesterol, and type 2 diabetes. Experts estimate that approximately 5% of the global population is affected by NASH, and it is expected to become even more prevalent.
“This phase 3 study (randomized, double-blind) brings an investigational treatment for NASH to patients in our Pottsville community,” said Dr. Glenn Freed, the Principal Investigator at Care Access - Pottsville. “This is an exciting opportunity for our community to participate in a major study for a serious disease that currently has few, if any, good treatment options.”
This research study is currently enrolling adults ages 18+ with evidence of NASH and stage 3 fibrosis. If you or someone you know is interested or wants to participate in this study, visit knowmynash.com, or contact Care Access at (351) 222-5112 to learn more.
Care Access first opened its doors in Pottsville in 2018, in collaboration with Dr. Freed and other local healthcare providers seeking to make clinical research more accessible. The local setting provides residents of Pottsville and surrounding communities the option to participate in clinical trials close to home.
About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.
To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.